{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:54:40Z","timestamp":1793915680047,"version":"4.8.0"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Myasthenia gravis (MG), primarily caused by acetylcholine receptor (AChR) autoantibodies, is a chronic autoimmune disorder causing severe muscle weakness and fatigability. In particular, seronegative MG constitutes 10%\u201315% of MG cases and presents diagnostic challenges especially in early-onset female patients who often show severe disease and resistance to immunosuppressive therapy. Furthermore, the immunopathology of seronegative MG remains unclear. Thus, in this study, we aimed to elucidate the pathogenic mechanism of seronegative MG using scRNA-seq analysis and plasma proteome analysis; in particular, we investigated the relationship between immune dysregulation status and disease severity in refractory seronegative MG. Employing single-cell RNA-sequencing and plasma proteome analyses, we analyzed peripheral blood samples from 30 women divided into three groups: 10 healthy controls, 10 early-onset AChR-positive MG, and 10 refractory early-onset seronegative MG patients, both before and after intravenous immunoglobulin treatment. The disease severity was evaluated using the MG-Activities of Daily Living (ADL), MG composite (MGC), and revised 15-item MG-Quality of Life (QOL) scales. We observed numerical abnormalities in multiple immune cells, particularly B cells, in patients with refractory seronegative MG, correlating with disease activity. Notably, severe MG cases had fewer regulatory T cells without functional abnormalities. Memory B cells were found to be enriched in peripheral blood cells compared with na\u00efve B cells. Moreover, plasma proteome analysis indicated significantly lower plasma protein levels of soluble CD22, expressed in the lineage of B-cell maturation (including mature B cells and memory B cells), in refractory seronegative MG patients than in healthy donors or patients with AChR-positive MG. Soluble CD22 levels were correlated with disease severity, B-cell frequency, and RNA expression levels of CD22. In summary, this study elucidates the immunopathology of refractory seronegative MG, highlighting immune disorders centered on B cells and diminished soluble CD22 levels. These insights pave the way for novel MG treatment strategies focused on B-cell biology.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1382320","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T12:53:30Z","timestamp":1713790410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuumi","family":"Okuzono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuuichi","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Itou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Sagara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Motegi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munenori","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dnyaneshwar","family":"Warude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kikukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14675","article-title":"Performance of different criteria for refractory myasthenia gravis","volume":"28","author":"Tran","year":"2021","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cen3.12731","article-title":"Japan MG registry: chronological surveys over 10\u2009years","volume":"14","author":"Suzuki","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1212\/WNL.38.4.514","article-title":"Seronegative myasthenia gravis","volume":"38","author":"Soliven","year":"1988","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010209","article-title":"Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis","volume":"95","author":"Tomschik","year":"2020","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: a multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13546","article-title":"Roles of cytokines and T cells in the pathogenesis of myasthenia gravis","volume":"203","author":"Uzawa","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.05.004","article-title":"Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis","volume":"332","author":"Jing","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-012-9685-0","article-title":"Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants","volume":"32","author":"Xu","year":"2012","journal-title":"J Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-021-00314-w","article-title":"Single-cell RNA-Seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis","volume":"7","author":"Jin","year":"2021","journal-title":"Cell Discovery"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.06.012","article-title":"Memory B cell resurgence requires repeated rituximab in myasthenia gravis","volume":"27","author":"Muto","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01006-9","article-title":"Memory B cells predict relapse in rituximab-treated myasthenia gravis","volume":"18","author":"Ruetsch-Chelli","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2007206117","article-title":"Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis","volume":"117","author":"Jiang","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13535","article-title":"Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis","volume":"1412","author":"Stathopoulos","year":"2018","journal-title":"Ann N Y Acad Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle Nerve"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0743-0","article-title":"Mapping systemic lupus erythematosus heterogeneity at the single-cell level","volume":"21","author":"Nehar-Belaid","year":"2020","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type\u2013specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1038\/s41467-021-25246-7","article-title":"Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis","volume":"12","author":"Wu","year":"2021","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136471","article-title":"Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses","volume":"5","author":"Jiang","year":"2020","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25198","article-title":"International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r","volume":"54","author":"Burns","year":"2016","journal-title":"Muscle Nerve"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","article-title":"DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors","volume":"8","author":"McGinnis","year":"2019","journal-title":"Cell Syst"},{"key":"B27","volume-title":"Elegant graphics for data analysis","author":"Wickham","year":"2016"},{"key":"B28","unstructured":"Automatically position non-overlapping text labels with \u201cggplot2\u201d. The R package version 0.8.2\n            GgrepelSK\n          2020"},{"key":"B29","unstructured":"nls2: nonlinear regression with brute force. R package version 0.2\n            GrothendieckG\n          2013"},{"key":"B30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","article-title":"T helper type 17 cells expand in patients with myasthenia-associated thymoma","volume":"76","author":"Wang","year":"2012","journal-title":"Scand J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-014-2039-3","article-title":"When do we judge IVIg for myasthenia gravis ineffective","volume":"36","author":"Takizawa","year":"2015","journal-title":"Neurol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.148","article-title":"Regulatory T cells in the treatment of disease","volume":"17","author":"Sharabi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaut.2015.09.005","article-title":"Suppression of experimental autoimmune myasthenia gravis by autologous T regulatory cells","volume":"67","author":"Aricha","year":"2016","journal-title":"J Autoimmun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08866-1","article-title":"Improving the efficacy of regulatory T cell therapy","volume":"62","author":"Baeten","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2008.11.015","article-title":"The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis","volume":"122","author":"Zhang","year":"2009","journal-title":"Immunol Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.09.012","article-title":"Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis","volume":"145","author":"Thiruppathi","year":"2012","journal-title":"Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3645157","DOI":"10.1155\/2020\/3645157","article-title":"Defects of CTLA-4 are associated with regulatory T cells in myasthenia gravis implicated by intravenous immunoglobulin therapy","volume":"2020","author":"Xu","year":"2020","journal-title":"Med Inflamm."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000945","article-title":"Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity","volume":"8","author":"Ashida","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-014-8985-1","article-title":"Intrathymic tfh\/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: central role in triggering MG occurrence","volume":"53","author":"Zhang","year":"2016","journal-title":"Mol Neurobiol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.808322","article-title":"Regulatory B cells are decreased and functionally impaired in myasthenia gravis patients","volume":"28","author":"Lin","year":"2022","journal-title":"Front Neurol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1285088","article-title":"In-depth blood immune profiling of Good syndrome patients","volume":"14","author":"Torres-Valle","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27140","article-title":"Reduced plasmablast frequency is associated with seronegative myasthenia gravis","volume":"63","author":"Guptill","year":"2021","journal-title":"Muscle Nerve"},{"key":"B44","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management","volume":"19","author":"Vanoli","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 Update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2013.09.006","article-title":"Disturbed B cell subpopulations and increased plasma cells in myasthenia gravis patients","volume":"264","author":"Kohler","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2011.00096","article-title":"Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22","volume":"2","author":"Jellusova","year":"2011","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131987","article-title":"Soluble CD22 as a tumor marker for hairy cell leukemia","volume":"112","author":"Matsushita","year":"2008","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1499-3872(15)60394-0","article-title":"Diagnostic and prognostic roles of soluble CD22 in patients with Gram-negative bacterial sepsis","volume":"14","author":"Jiang","year":"2015","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abm5667","article-title":"Associations of plasma soluble CD22 levels with brain amyloid burden and cognitive decline in Alzheimer\u2019s disease","volume":"8","author":"Bu","year":"2022","journal-title":"Sci Adv"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.6.2987","article-title":"Dysregulated expression of the Cd22 gene as a result of a short interspersed nucleotide element insertion in Cd22a lupus-prone mice","volume":"165","author":"Mary","year":"2000","journal-title":"J Immunol"},{"key":"B52","first-page":"27","article-title":"Altered CD19\/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus","volume":"16","author":"El-Sayed","year":"2009","journal-title":"Egypt J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-006-0497-z","article-title":"CD19\/22 balance relates to improvement of disease activity in systemic lupus erythematosus","volume":"16","author":"Suzuki","year":"2006","journal-title":"Mod Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodr\u00edguez Cruz","year":"2015","journal-title":"JAMA Neurol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1382320\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T12:53:36Z","timestamp":1713790416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1382320\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,22]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2024.1382320"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1382320","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,22]]},"article-number":"1382320"}}